To evaluate the ocular tolerance of T1225 1% and 1.5% eye drops versus vehicle after one instillation twice-daily (morning and evening), in one eye, during 3 days (from Day 0 to Day 2).

To assess azithromycin tear, conjunctiva and plasmatic concentrations, after a 3-day treatment period

The aim of the present study was to compare ocular tolerance and safety after repeated instillations of T1225 1% and 1.5% eye drops and vehicle and to assess the residual azithromycin concentrations in tear, ocular conjunctiva and plasma samples, approximately 12 hours after the last Investigational Medicinal Product instillation.

Inclusion Criteria:

• Male or female aged from 18 to 45 years old;
• Written informed consent;
• Healthy volunteers without any subjective ocular symptom;
• Normal ocular examination in both eyes (corrected visual acuity >= 6/10, normal slit lamp examination, tear prism height > 0.1mm, tear break-up time (BUT) >= 10 seconds, lissamine green test score < 4);
• Registered, or agreed to be registered, in the national register of healthy volunteers

Exclusion Criteria:

• Ocular trauma, infection or inflammation within the last 3 months;
• number of corneal stained punctuations Ocular trauma, infection or inflammation within the last 3 months;
• number of corneal stained punctuations >= 5;
• blepharitis, conjunctivitis, uveitis;
• contact lenses;
• topical ocular treatment within the last month;
• ocular laser within the last 3 months;
• ocular surgery, including LASIK and PRK, within the last 12 months;
• systemic macrolide within the last month;
• medication during the study (except: paracetamol and contraceptives).